LivaNova PLC (LIVN) |
|
43.88 0.22 (0.5%)
|
03-22 12:03 |
|
Open: |
43.66 |
Pre. Close: |
43.66 |
|
High:
|
44.17 |
Low:
|
43.035 |
|
Volume:
|
172,998 |
Market Cap:
|
2,350(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:47:52 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 58.41 One year: 65.45 |
| Support: |
Support1: 40.25 Support2: 33.49 |
| Resistance: |
Resistance1: 50.01 Resistance2: 56.04 |
| Pivot: |
43.32  |
| Moving Average: |
MA(5): 43.21  MA(20): 44.49
MA(100): 52.08 MA(250): 58.72 |
| MACD: |
MACD(12,26): -2.5 Signal(9): -2.9 |
| Stochastic oscillator: |
%K(14,3): 48.1 %D(3): 39 |
| RSI: |
RSI(14): 37.6 |
| 52-week: |
High: 88 Low: 40.25 |
| Average Vol(K): |
3-Month: 518 (K) 10-Days: 665 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LIVN ] has closed below upper band by 39.9%. Bollinger Bands are 11.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
44.62 - 44.78 |
44.78 - 44.92 |
|
Low:
|
42.52 - 42.72 |
42.72 - 42.9 |
|
Close:
|
43.35 - 43.62 |
43.62 - 43.88 |
|
Company Description |
|
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom. |
Headline News |
Wed, 22 Mar 2023
LivaNova to Announce First-Quarter 2023 Results - LivaNova ... - Benzinga
Wed, 22 Mar 2023
Harbour Capital Advisors LLC Acquires Shares of 4125 LivaNova ... - MarketBeat
Sat, 18 Mar 2023
Swiss National Bank Buys 2600 Shares of LivaNova PLC (NASDAQ ... - MarketBeat
Sat, 11 Mar 2023
Stock Holdings of LivaNova PLC (NASDAQ:LIVN) Hsbc Holdings ... - Best Stocks
Thu, 09 Mar 2023
LivaNova to Present at the Barclays Global Healthcare Conference - Joplin Globe
Thu, 09 Mar 2023
LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
54 (M) |
| Shares Float |
53 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
108.3 (%) |
|
Shares Short
|
2,170 (K) |
|
Shares Short P.Month
|
2,090 (K) |
Stock Financials |
|
EPS
|
-8.48 |
|
EPS Est Next Qtl
|
0.8 |
|
EPS Est This Year
|
3.25 |
|
EPS Est Next Year
|
3.51 |
|
Book Value (p.s.)
|
21.81 |
|
Profit Margin (%)
|
-9.2 |
|
Operating Margin (%)
|
13.3 |
|
Return on Assets (ttm)
|
3.8 |
|
Return on Equity (ttm)
|
-7.6 |
|
Qtrly Rev. Growth
|
-0.3 |
|
Gross Profit (p.s.)
|
13.03 |
|
Sales Per Share
|
19.05 |
|
EBITDA (p.s.)
|
3.42 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
85 (M) |
|
Levered Free Cash Flow
|
-162 (M) |
Stock Valuations |
|
PE Ratio
|
-5.2 |
|
PEG Ratio
|
-5.3 |
|
Price to Book value
|
2.01 |
|
Price to Sales
|
2.3 |
|
Price to Cash Flow
|
27.81 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
